{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:59:21Z","timestamp":1773622761403,"version":"3.50.1"},"reference-count":19,"publisher":"Pleiades Publishing Ltd","issue":"11","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biochemistry Moscow"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1134\/s000629791611016x","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T04:27:58Z","timestamp":1478924878000},"page":"1396-1400","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunogenicity of human interferon-beta-containing pharmaceuticals"],"prefix":"10.1134","volume":"81","author":[{"given":"V. D.","family":"Nazarov","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. V.","family":"Lapin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. V.","family":"Mazing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E. P.","family":"Evdoshenko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. A.","family":"Totolian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"137","published-online":{"date-parts":[[2016,11,13]]},"reference":[{"key":"347_CR1","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/nbt0708-743","volume":"26","author":"R. Rader","year":"2008","unstructured":"Rader, R. (2008) Redefining biopharmaceutical, Nat. Biotechnol., 26, 743\u2013751.","journal-title":"Nat. Biotechnol."},{"key":"347_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2174\/138920006774832604","volume":"7","author":"A. Baumann","year":"2006","unstructured":"Baumann, A. (2006) Early development of therapeutic biologics\u2013pharmacokinetics, Curr. Drug Metab., 7, 15\u201321.","journal-title":"Curr. Drug Metab."},{"key":"347_CR3","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.biologicals.2015.06.004","volume":"43","author":"M. Wadhwa","year":"2015","unstructured":"Wadhwa, M., Knezevic, I., Kang, H. N., and Thorpe, R. (2015) Immunogenicity assessment of biotherapeutic products: an overview of assays and their utility, Biologicals, 43, 298\u2013306.","journal-title":"Biologicals"},{"key":"347_CR4","unstructured":"WHO. Guidelines on clinical evaluation of vaccines: regulatory expectations (2004) WHO Tech Rep., 924, 35\u2013102."},{"key":"347_CR5","first-page":"14731484","volume":"7","author":"M. M. C. Van Beers","year":"2012","unstructured":"Van Beers, M. M. C., and Bardor, M. (2012) Minimizing immunogenicity of biopharmaceuticals by controlling critical quality attributes of proteins, Biotechnol. J., 7, 14731484.","journal-title":"Biotechnol. J."},{"key":"347_CR6","doi-asserted-by":"publisher","first-page":"235","DOI":"10.15789\/1563-0625-2015-3-235-244","volume":"17","author":"V. D. Nazarov","year":"2015","unstructured":"Nazarov, V. D., Lapin, S. V., Surkova, E. A., Evdoshenko, E. P., Makshakov, G. S., and Totolian, A. A. (2015) Diagnostic and prognostic significance of intrathecal synthesis of immunoglobulin free light chains in multiple sclerosis, Med. Immunol. (Moscow), 17, 235\u2013244.","journal-title":"Med. Immunol. (Moscow)"},{"key":"347_CR7","first-page":"1871","volume":"32","author":"S. Nikfar","year":"2010","unstructured":"Nikfar, S., Rahimi, R., and Abdollahi, M. (2010) A metaanalysis of the efficacy and tolerability of interferon-\u00df in multiple sclerosis, overall and by drug and disease type, Clin. Ther., 32, 1871\u20131888.","journal-title":"overall and by drug and disease type, Clin. Ther."},{"key":"347_CR8","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00228-015-1921-0","volume":"71","author":"K. Govindappa","year":"2015","unstructured":"Govindappa, K., Sathish, J., Park, K., Kirkham, J., and Pirmohamed, M. (2015) Development of interferon betaneutralizing antibodies in multiple sclerosis\u2013a systematic review and meta-analysis, Eur. J. Clin. Pharmacol., 71, 1287\u20131298.","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"347_CR9","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1089\/jir.2010.0086","volume":"30","author":"M. M. Van Beers","year":"2010","unstructured":"Van Beers, M. M., Jiskoot, W., and Schellekens, H. (2010) On the role of aggregates in the immunogenicity of recombinant human interferon beta in patients with multiple sclerosis, J. Interf. Cytokine Res., 30, 767\u2013775.","journal-title":"J. Interf. Cytokine Res."},{"key":"347_CR10","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1016\/S1474-4422(10)70103-4","volume":"9","author":"C. H. Polman","year":"2010","unstructured":"Polman, C. H., Bertolotto, A., Deisenhammer, F., Giovannoni, G., Hartung, H. P., Hemmer, B., Killestein, J., McFarland, H. F., Oger, J., Pachner, A. R., Petkau, J., Reder, A. T., Reingold, S. C., Schellekens, H., and Sorensen, P. S. (2010) Recommendations for clinical use of data on neutralizing antibodies to interferon-beta therapy in multiple sclerosis, Lancet Neurol., 9, 740\u2013750.","journal-title":"Lancet Neurol."},{"key":"347_CR11","unstructured":"WHO Expert Committee on Biological Standardization. Thirty-fifth report (1985) World Health Organ. Tech. Rep. Ser., 725, 1\u2013140."},{"key":"347_CR12","first-page":"938","volume":"34","author":"F. Deisenhammer","year":"2014","unstructured":"Deisenhammer, F. (2014) Interferon-beta: neutralizing antibodies, binding antibodies, pharmacokinetics and pharmacodynamics, and clinical outcomes, J. Interferon Cytokine Res., 34, 938\u2013945.","journal-title":"binding antibodies, pharmacokinetics and pharmacodynamics, and clinical outcomes, J. Interferon Cytokine Res."},{"key":"347_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.jim.2008.03.014","volume":"336","author":"R. Lam","year":"2008","unstructured":"Lam, R., Farrell, R., Aziz, T., Gibbs, E., Giovannoni, G., Gro\u00dfsberg, S., and Oger, J. (2008) Validating parameters of a luciferase reporter gene assay to measure neutralizing antibodies to IFN\u00df in multiple sclerosis patients, J. Immunol. Methods, 336, 113\u2013118.","journal-title":"J. Immunol. Methods"},{"key":"347_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/S0022-1759(03)00203-5","volume":"278","author":"Y. Kawade","year":"2003","unstructured":"Kawade, Y., Finter, N., and Grossberg, S. E. (2003) Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity, J. Immunol. Methods, 278, 127\u2013144.","journal-title":"J. Immunol. Methods"},{"key":"347_CR15","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1089\/jir.2010.0113","volume":"31","author":"A. Meager","year":"2011","unstructured":"Meager, A., Dolman, C., Dilger, P., Bird, C., Giovannoni, G., Schellekens, H., Thorpe, R., and Wadhwa, M. (2011) An assessment of biological potency and molecular characteristics of different innovator and noninnovator interferon-beta products, J. Interferon Cytokine Res., 31, 383\u2013392.","journal-title":"J. Interferon Cytokine Res."},{"key":"347_CR16","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1177\/1352458506070941","volume":"12","author":"C. Gneiss","year":"2006","unstructured":"Gneiss, C., Tripp, P., Reichartseder, F., Egg, R., Ehling, R., Lutterotti, A., Khalil, M., Kuenz, B., Mayringer, I., Reindl, M., Berger, T., and Deisenhammer, F. (2006) Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients, Mult. Scler., 12, 731\u2013737.","journal-title":"Mult. Scler."},{"key":"347_CR17","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1191\/1352458506ms1272oa","volume":"12","author":"C. Ro\u00dfs","year":"2006","unstructured":"Ro\u00dfs, C., Clemmesen, K. M., Sorensen, P. S., KochHenriksen, N., and Bendtzen, K. (2006) Measuring and evaluating interferon \u00df-induced antibodies in patients with multiple sclerosis, Mult. Scler., 12, 39\u201346.","journal-title":"Mult. Scler."},{"key":"347_CR18","first-page":"321","volume":"4","author":"F. Manfredonia","year":"2008","unstructured":"Manfredonia, F., Pasquali, L., Dardano, A., Iudice, A., Murri, L., and Monzani, F. (2008) Review of the clinical evidence for interferon \u00df 1a (Rebif) in the treatment of multiple sclerosis, Neuropsychiatr. Dis. Treat., 4, 321\u2013336.","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"347_CR19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1212\/WNL.43.4.655","volume":"43","author":"The IFNB Multiple Sclerosis Study Group","year":"1993","unstructured":"The IFNB Multiple Sclerosis Study Group (1993) Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial, Neurology, 43, 655\u2013661.","journal-title":"Neurology"}],"container-title":["Biochemistry (Moscow)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S000629791611016X.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1134\/S000629791611016X","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1134\/S000629791611016X.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:08:15Z","timestamp":1773619695000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1134\/S000629791611016X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["347"],"URL":"https:\/\/doi.org\/10.1134\/s000629791611016x","relation":{},"ISSN":["0006-2979","1608-3040"],"issn-type":[{"value":"0006-2979","type":"print"},{"value":"1608-3040","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"13 June 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}